Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – can be dealing with Level of competition from an easier-to-dose alternative from Sling Therapeutics. The inflammation can drive the eyes forward or trigger the eyes